Decobel - Decobel is a glucocorticosteroid. This medication Inhibits the function of leukocytes and tissue macrophages. Decobel restricts the migration of leukocytes in the area of inflammation. This drug violates the ability of macrophages to phagocytosis and the formation of interleukin-1. Decobel decreases capillary permeability caused by histamine release. This medicine inhibits the activity of fibroblasts and collagen formation.
Decobel inhibits the activity of phospholipase A2, which leads to suppression of the synthesis of prostaglandins and leukotrienes.
With direct application to the vessels this drug has a vasoconstrictor effect.
Decobel has a pronounced dose-dependent effect on the metabolism of carbohydrates, proteins and fats.
In high doses Decobel may increase the excitability of brain tissue and contributes to lowering the threshold of convulsive readiness.
With systemic use of therapeutic activity of Decobel is due to anti-inflammatory, antiallergic, immunosuppressive and antiproliferative action.
For external and local use of therapeutic activity of Decobel is due to anti-inflammatory, antiallergic and antiexudative (due to vasoconstrictor effect) effect.
Anti-inflammatory,As a screening test for Cushing’s syndrome,Acute exacerbations in multiple sclerosis,Unresponsive shock,Bacterial meningitis,Prophylaxis of nausea and vomiting associated with cytotoxic therapy,Cerebral oedema caused by malignancy,Ocular inflammation,Inflammatory joint diseases.